Sofosbuvir Intermedium CAS 21382-82-1 Puritas ≥98.0% (HPLC)
Commercial Supple Sofosbuvir et media intermedia:
Sofosbuvir CAS: 1190307-88-0
N4-Benzoylcytosine CAS: 26661-13-2
triphenyl(1-[ethoxycarbonyl]ethylidene) phosphorane CAS: 21382-82-1
Pentafluorophenol CAS: 771-61-9
N-[(S)-(2,3,4,5,6-pentafluorophenoxy)phenoxyphosphinyl]-L-alanine 1-Methylethyl ester CAS: 1334513-02-8
Nomen | triphenyl(1-[ethoxycarbonyl]ethylidene) phosphorane |
Synonyma | 2-(triphenyl-phosphanylidene) -propionicum acidum ethyl ester |
CAS Number | 21382-82-1 |
CATTUS Number | RF-PI179 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | C23H23O2P |
M. Pondus | 362.41 |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Flavus pulveris |
Puritas / Analysis Methodus | ≥98.0% (HPLC) |
Damnum in Siccatio | ≤1.0% (60℃, 2h) |
Summa PH3P+PH3PO | ≤2.0% (HPLC) |
Substantia cognata non specificata | ≤0.5% (HPLC) |
Test Standard | Enterprise Standard |
Consuetudinem | Medium Sofosbuvir (CAS: 1190307-88-0) |
sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, umore et peste infestatione.
![1](https://www.ruifuchemical.com/uploads/15.jpg)
![](https://www.ruifuchemical.com/uploads/23.jpg)
Manufacturer cum High puritate et stabulo Quality
Supple Commercial Sofosbuvir (CAS: 1190307-88-0) et intermedia relativa:
Sofosbuvir CAS: 1190307-88-0
N4-Benzoylcytosine CAS: 26661-13-2
triphenyl(1-[ethoxycarbonyl]ethylidene) phosphorane CAS: 21382-82-1
L-Alanine Isopropyl Ester Hydrochloride CAS: 62062-65-1
Pentafluorophenol CAS: 771-61-9
N-[(S)-(2,3,4,5,6-pentafluorophenoxy)phenoxyphosphinyl]-L-alanine 1-Methylethyl ester CAS: 1334513-02-8
Sofosbuvir medicamentum adhibitum est ad hepatitis curationem C. Commendatur utendum in compositione cum aliis medicamentis (ut velpatasvir) pro genotypes primi lineae curationis HCV 1, 2, 3, 4, 5 et 6; Effectum accipit per inhibitorem nucleotidis analogi agendi, capax est specialiter inhibendi HCV NS5B (dapibus non-structuralibus 5B) RNA-dependens RNA polymerasis.